Lexaria Bioscience Corp. LXRP Archives - Page 3 of 27

WednesdayJan 22, 2020 12:35 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Inks Licensing Deal with Smokeless Cannadips CBD Product Maker

Lexaria Bioscience is a company dedicated to developing effective oral ingestion methods for drug substances that rival the rapid-delivery qualities of more health-dangerous inhaled-drug products. Inhalation is a particularly popular method of using tobacco and cannabis products, despite government warnings about the scientifically established dangers of doing so Lexaria has been boosting its profile and revenue potential through licensing agreements with other companies Lexaria recently announced a licensing agreement with Cannadips CBD-maker The Boldt Runners Corporation The agreement grants Cannadips CBD use of Lexaria’s DehydraTECH IP to improve the speed of its effectiveness and to combat the throat irritation that…

WednesdayJan 22, 2020 10:00 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Provide Patented DehydraTECH(TM) to Cannadips’ Cannabis Products in California and Across the US

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has reached a new definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips' cannabis products, both in its current California market and across the United States. According to the update, Lexaria's DehydraTECH fast-acting, high-absorption technology is perfectly suited to improve consumer satisfaction and the dipping experience. Terpene-rich multi spectrum oils are base ingredients of Cannadips THC, and DehydraTECH is able to reduce throat irritation normally associated with some terpenes. Inferior products utilize less efficacious cannabis isolate without terpenes that lack the entourage…

ThursdayJan 16, 2020 1:01 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expects Sustainable Revenue Growth, Plans New Capital Markets Strategy in 2020

Growing interest in the company’s innovative DehydraTECH™ drug delivery platform from large global corporations Lexaria’s strategy to be listed on a nationally recognized U.S. exchange will help the company access a significantly larger audience of investors Lexaria has 16 patents with another 60 pending worldwide and is the only company to hold a patent for improved delivery of all non-psychoactive cannabinoids Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, has achieved virtually everything it set out to do in 2019 and has even bigger plans for 2020 that include achieving higher revenue and being listed…

WednesdayJan 15, 2020 1:29 pm

Concerns About Vape Addiction, Injury Provide Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) with Opportunity

Lexaria Bioscience continues to advance the effectiveness of its proprietary DehydraTECH technology, a formulation that teams with drug substances such as nicotine and cannabidiol to quickly carry those drugs into a user’s blood stream Recent concerns about the safety of vape products and ongoing concerns about the safety of tobacco are opening doors to Lexaria’s edible technology Newly legalized cannabis-infused edibles began hitting store shelves nationwide in Canada last month, presenting Lexaria with new potential licensing outlets for its increasingly effective products If 2019 was the year when vape users discovered the potential perils of using untested off-brand products, 2020…

TuesdayJan 14, 2020 10:03 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Agreement to Provide DehydraTECH(TM) Technology to Cannadips CBD

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, this morning announced that it has reached a definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips CBD, the Original Smokeless CBD Dip Brand. According to the update, each tin of Cannadips contains 15 pouches, each with 10mg of hemp-derived CBD, and includes only natural sweeteners with no tobacco or nicotine. Already established as the leader in CBD oral delivery, Lexaria has been working behind the scenes with the Boldt Runners team to elevate the product experience. “In our quest to create the ultimate smokeless, oral…

MondayJan 13, 2020 2:22 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Platform Boosts CBD Absorption Levels

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative DehydraTECH(TM) delivery platform is patented for all nonpsychoactive cannabinoids as well as for tetrahydrocannabinol (THC) and psychoactive cannabinoids. An article discussing the company reads, “Medical researchers have struggled to find ways to penetrate the blood brain barrier effectively to transport beneficial drugs for many years. This barrier exists to block toxic or otherwise dangerous substances from entering the brain and is formed by layers of microvascular endothelial cells inside blood vessels. Lexaria’s DehydraTECH(TM) drug delivery platform brings beneficial drugs to the brain faster. . . . In June 2019, Lexaria completed a series…

FridayJan 10, 2020 9:22 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Posts Strategic Company Update

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, on Thursday provided a strategic update from the company’s CEO Chris Bunka. Among other highlights, the update includes a brief recap of achievements from 2019 and an outlook for the new year. “One objective for the company during 2020 is to dramatically alter our capital markets strategy. During the last six months Lexaria has met with a number of Wall Street investment banking firms as we devise our long-term capital markets strategy. Lexaria expects to pursue a strategy during 2020 to qualify for listing on a nationally-recognized US…

ThursdayJan 09, 2020 12:34 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Holds Key Position as Edible Cannabis Market Opens Wide

Canada’s first nationally legal cannabis-infused edible products began hitting store shelves December 17, vastly broadening the market for products using the plant’s extracts Lexaria Bioscience has dedicated years of research to the development of its proprietary DehydraTECH technology, designed to enhance the effectiveness of orally consumed drug products such as cannabis as well as nicotine Testing of Lexaria’s 2.0 version of its DehydraTECH technology shows enormous improvement in the speed of payload delivery to the bloodstream, as well as the potential for delivering drugs across the body’s largely impenetrable blood-brain barrier to the central nervous system Canada’s regulatory innovations in…

WednesdayJan 08, 2020 11:28 am

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Patented DehydraTECH™ Platform Increases CBD Tissue Absorption by 1,937%

DehydraTECH™ drug delivery platform achieved a 319% higher CBD blood concentration level at 60 minutes than the generic coconut oil formulation The technology can be used on the nicotine market, the pharmaceutical market, and the cannabinoid market No other company in the world has a patent for improved delivery of all non-psychoactive cannabinoids Partnership with one of the world’s largest tobacco companies with up to $12 million in Lexaria funding for clinical investigations and product development Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has launched a revolutionary technology that accelerates intestinal absorption of bioactive substances administered without the need for…

FridayDec 20, 2019 2:14 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Drug-Delivery Platform Continues Reaching New Milestones

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently announced further advances in its proprietary, oral, drug-delivery platform: DehydraTECH(TM). An article discussing the company reads, “Lexaria’s early pilot-stage human trials with tetrahydrocannabinol (THC) delivery show its newest formulation of DehydraTECH-enhanced edibles begin providing cannabinoid effectiveness in less than 10 minutes, which is about twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations, according to a company news release (http://ibn.fm/mwAS9). . . . Lexaria has been developing DehydraTECH solutions as alternatives to smoked or vaped drug delivery over the course…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP